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Objective. Assessment of cytology and biopsy results preceding cervical excisional treatment and their
associationwith excisional histology, to evaluate compliancewith treatment recommendations and the potential
effect of revisions in cervical histology terminology and usage.
Method.Data fromaunique statewidepopulation-based screening registrywas used todescribe the use andhis-
tologic outcomes of cervical excisional procedures in the year following an abnormal cervical screening cytology.
Results. From 2007 to 2011, LEEP rates decreased 87%, 45%, and 16% for women aged 15–20, 21–24, and
25–29 years, respectively. Reductions were attributable to an overall decline in cervical screening and colposcopy,
and a decrease in LEEP following a diagnosis of less than cervical intraepithelial neoplasia grade 2 (bCIN2) or CIN2
histology precededby any abnormal cytology other than high-grade squamous intraepithelial lesion (bHSIL). LEEP
rates did not change signiﬁcantly (p N 0.7) for women aged 30–39 years. Irrespective of age, CIN2 was the most
common histologic antecedent of excisional treatment (42%), with most (80%) preceded by bHSIL cytology.
Conclusion. Cervical excisions are an unavoidable consequence of cervical screening. Adherence to treatment
guidelines stipulating conservative follow-up of young women with biopsies ≤CIN2 could signiﬁcantly decrease
the number of excisional procedures and associated harms. This opportunity will be lost if cervical intraepithelial
neoplasia grade 3 (CIN3) and some or all of CIN2 aremerged into a single histologic category, as has been recently
recommended in the United States.© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. tipulating conservative follow-
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In March 2012, the United States Preventive Services Task Force
(USPSTF), the American Cancer Society (ACS), the American Society for
Colposcopy and Clinical Pathology (ASCCP), and the American Society
for Clinical Pathology (ASCP) releasednewguidelines recommending cer-
vical screening at three-year intervals starting at age 21, with the option
to substitute cytology plus human papillomavirus (HPV) DNA testing
(“cotesting”) at ﬁve-year intervals starting at the age of 30. The cotesting
regimenwas preferred for women aged 30 years and above by all groups
except the USPSTF [1, 2].se. 
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awoman's lifetime that has been the focus of guideline changes over the
past decade, are driven by the recognition that screening is not without
harms and thatmany if notmost of the lesions treated as a consequence
of screening would not have progressed to cancer [3, 4]. Sasieni et al.
showed that screeningwomen 20–24 years old has no effect on cervical
cancer incidence up to age 30 [6]. For women aged 13–25 years in
Kaiser Northern California, 68% of cervical intraepithelial neoplasia
grade 2 (CIN2) resolves spontaneously within 3 years, supporting the
recommendation that observation is preferred over treatment in
young women [7, 8].
Concerns have been raised about risks of preterm birth, premature
rupture of membranes, low birth-weight, and cesarean section follow-
ing cervical excisional treatment [9–11]. In addition, the discomfort,
anxiety, and negative impact on sexual function that have been associ-
ated with excisional treatment are of concern in circumstances where
treatment may not contribute to cancer prevention. The risk/beneﬁt
calculation for treatment is least favorable in youngwomen, prompting
the June, 2009, Practice Improvement in Cervical Screening and
Management (PICSM) symposium and, subsequently, the American Col-
lege of Obstetrics and Gynecology (ACOG) to recommend discontinuing
cervical screening in women younger than age 21 [5]. Despite the low
risk for cervical precancer (cervical intraepithelial neoplasia grade 3;
CIN3) and cervical cancer in young women and the potential harms of
excisional procedures, studies involving provider responses to hypothet-
ical clinical scenarios suggest major deviations in cervical screening
practice from clinical practice recommendations, with reﬂex HPV testing
done for high-grade cytology, testing for low-risk HPV, and screening
annually with all tests regardless of the clinical situation as the most
common preference of survey respondents [12–15].
Prior to this assessment, the association of cervical screening and
excisional treatment has never been investigated in actual practice in
the United States (US), and modeling studies are hampered by the
assumption that clinical practice guidelines are followed, which the
investigations of screening practices cited above suggest may be signif-
icantly inaccurate. It is also recognized that self-selection by respon-
dents to studies of clinical vignettes may not produce a representative
sample of care providers, and thereby reﬂect an imperfect view of
provider compliance with guideline recommendations. Using data
from a population-based statewide surveillance program, we sought
to quantify the utilization of excisional treatment associated with
cervical screening by age, to infer the actual indications for excisional
treatment from the antecedent cytology and biopsy diagnoses, and to
examine the diagnostic yield of CIN3+ associated with different
combinations of antecedent test results.
Materials and methods
The New Mexico HPV Pap Registry (NMHPVPR) is located at the
University of New Mexico and acts as a designee of the New Mexico
Department of Health (NMDOH). The NMHPVPR operates under New
Mexico Administrative Code (NMAC) 7.4.3, which speciﬁes the list of
Notiﬁable Diseases and Conditions for the state of New Mexico. In
2006, with the intention of monitoring cervical screening practices
and outcomes and the impact of HPV vaccination, NMAC 7.4.3 speciﬁed
that laboratoriesmust report to the NMHPVPR all cervical or vaginal cy-
tology, cervical pathology, and HPV tests performed onwomen residing
in NewMexico. NMAC 7.4.3 was updated in 2009 to include vulvar and
vaginal pathology (http://nmhealth.org/ERD/healthdata/documents/
NotiﬁableDiseasesConditions022912ﬁnal.pdf). Ongoing evaluations of
cervical screening, diagnosis and treatment by the NMHPVPR have
been reviewed and approved under exempt status by the University
of New Mexico Human Research Review Committee.
In this analysis we used the NMHPVPR database to investigate the
use of cervical excisional treatment over the period of 2007 through
2011 in New Mexico among women aged 15–39 years. The majority(80%) of cervical excisional procedures in which the method of excision
was describedwere identiﬁed as loop electrosurgical excision procedure
(LEEP). When not identiﬁed as LEEP, excisional procedures were gener-
ally identiﬁed only as cone biopsy (without specifying the excisional
method), or infrequently as cold knife conization. Therefore, we elected
not to attempt to stratify cervical excisional procedures by method of
excision. Hysterectomy and the rarely used trachelectomy were not
included as excisional treatment for the purposes of this analysis.
We evaluated the use of cervical excisional treatment by considering
the likelihood that awomanwould undergo excisionwithin 1 year of an
abnormal screening cervical cytology test with a result of atypical cells
of unknown signiﬁcance (ASC-US) or worse. We deﬁned a screening
cervical cytology test as one without any prior cervical cytology within
10 months (300 days) based on our earlier published ﬁndings [16].
We further restricted this analysis to those screening cytology tests
without any preceding abnormal cervical cytology or histology within
15 months, andwithout any prior excisional procedure in the database.
If a woman had more than one such cervical cytology test during the
period of 2007–2010 we chose the earliest and refer to this as the
“index” screening cytology exam. A total of 39,804 abnormal index
screening cytology exams were identiﬁed, as were 2236 excisional
procedures in the year following these index screens.
We calculated the proportion of women undergoing excisional
treatment within 1 year of the abnormal index screening cytology
within strata deﬁned by the cytologic result of the index screen and
the histologic result of the follow-up cervical biopsy or endocervical cu-
rettage (ECC). Abnormal cytologic results were classiﬁed as ASC-US
[negative for high-risk HPV or HPV status unknown], ASC-US+ [positive
for high-risk HPV; high risk HPV types are based on Hybrid Capture 2
(Germantown, MD, USA) clinical HPV assay results which detect HPV
types, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68], low-grade
intraepithelial lesion (LSIL), atypical squamous cells-cannot rule out
high-grade (ASC-H), atypical glandular cells (AGC), and high-grade
intraepithelial lesion (HSIL) and less than HSIL (bHSIL) which included
ASC-US, ASC-US+, LSIL, ASC-H, and AGC. Cytologic results of carcinoma
were classiﬁed asHSIL. TheHPV status of ASC-US resultswas determined
by linking the index cytology with a separate database of HPV tests.
Cervical biopsy results were classiﬁed as negative, cervical
intraepithelial neoplasia grades 1, 2 and 3 (CIN1, CIN2, CIN3), carcinoma
in situ (CIS), adenocarcinoma in situ (AIS), and cancer. The histologic
interpretation CIN1–2 is included with CIN2, and CIN2–3 is included
with CIN3. This is believed to represent current clinical practice, provides
the most charitable view of the indications for excisional treatment, and
recognizes the reported irreproducibility of these histologic designations,
though it is understood that there is, at present, no published data about
subsequent cancer risk to validate these choices.
We also computed population rates of cervical excision for the
period 2007–2011. These rates were computed as the number of
women treated in a given calendar year per 10,000 women in the
population and also per 10,000 women receiving a screening cervical
cytology test. New Mexico population counts are US Census estimates
(www.census.gov). Using the 2007–2010 Centers for Disease Control
bridged-race population ﬁles, 42.2% of NM women were non-Hispanic
white, 42.2% were Hispanic white, 3.0% were African American, 10.5%
were American Indian, and 1.9% were Asian.
Data analysis was conducted using SAS version 9.3. Conﬁdence
intervals for population excisional treatment rates are based on normal
approximation and all conﬁdence intervals for proportions are exact.
Signiﬁcance testing with the Cochran–Armitage test of linear trend
was employed to discern changes over time.
Results
The rate of excisional treatment for cervical abnormalities decreased
in NewMexico over the period 2007–2011 for women b30 years of age
(Table 1). The decrease was greatest for women aged 15–20 years,
Table 1
Cervical excision (LEEP) rates in NewMexico for women 15–39 years old, 2007–2011a.
LEEPs per 10,000 women LEEPs per 10,000 women screened
Age Year LEEPs Women Rate (95% CI) Women screened Rate (95% CI)
15–20 years 2007 158 87,944 18.0 (15.2–20.8) 21,068 75.0 (63.3–86.7)
2008 118 87,830 13.4 (11.0–15.9) 19,735 59.8 (49.0–70.6)
2009 77 87,679 8.8 (6.8–10.7) 17,902 43.0 (33.4–52.6)
2010 29 87,610 3.3 (2.1–4.5) 11,261 25.8 (16.4–35.1)
2011 20 85,420 2.3 (1.3–3.4) 7288 27.4 (15.4–39.5)
p b 0.0001 p b 0.0001
21–24 years 2007 278 54,696 50.8 (44.9–56.8) 24,272 114.5 (101.1–128.0)
2008 240 54,824 43.8 (38.2–49.3) 23,745 101.1 (88.3–113.9)
2009 265 54,825 48.3 (42.5–54.2) 22,827 116.1 (102.1–130.1)
2010 180 54,941 32.8 (28.0–37.5) 21,494 83.7 (71.5–96.0)
2011 160 56,925 28.1 (23.8–32.5) 20,550 77.9 (65.8–89.9)
p b 0.0001 p b 0.0001
25–29 years 2007 270 66,629 40.5 (35.7–45.4) 28,780 93.8 (82.6–105.0)
2008 301 67,363 44.7 (39.6–49.7) 29,080 103.5 (91.8–115.2)
2009 329 67,971 48.4 (43.2–53.6) 28,457 115.6 (103.1–128.1)
2010 266 68,306 38.9 (34.3–43.6) 26,888 98.9 (87.0–110.8)
2011 236 69,169 34.1 (29.8–38.5) 25,673 91.9 (80.2–103.7)
p = 0.02 p = 0.7
30–34 years 2007 185 58,603 31.6 (27.0–36.1) 24,438 75.7 (64.8–86.6)
2008 203 59,205 34.3 (29.6–39.0) 24,502 82.9 (71.5–94.2)
2009 200 61,055 32.8 (28.2–37.3) 24,026 83.2 (71.7–94.8)
2010 190 63,234 30.0 (25.8–34.3) 23,554 80.7 (69.2–92.1)
2011 210 64,717 32.4 (28.1–36.8) 22,392 93.8 (81.1–106.5)
p = 0.7 p = 0.07
35–39 years 2007 130 62,665 20.7 (17.2–24.3) 23,170 56.1 (46.5–65.8)
2008 132 62,543 21.1 (17.5–24.7) 22,936 57.6 (47.7–67.4)
2009 127 62,645 20.3 (16.7–23.8) 22,293 57.0 (47.1–66.9)
2010 113 61,762 18.3 (14.9–21.7) 20,366 55.5 (45.3–65.7)
2011 129 60,634 21.3 (17.6–24.9) 19,013 67.8 (56.1–79.6)
p = 0.8 p = 0.2
Total 2007 1021 330,537 30.9 (29.0–32.8) 121,728 83.9 (78.7–89.0)
2008 994 331,765 30.0 (28.1–31.8) 119,998 82.8 (77.7–88.0)
2009 998 334,175 29.9 (28.0–31.7) 115,505 86.4 (81.0–91.8)
2010 778 335,853 23.2 (21.5–24.8) 103,563 75.1 (69.8–80.4)
2011 755 336,865 22.4 (20.8–24.0) 94,916 79.5 (73.9–85.2)
p b 0.0001 p b 0.06
a p-Values are for test of trend in rates over the ﬁve year period.
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aged 21–24 years decreased by 45%, and in women aged 25–29 years
by 16%. Excision rates did not change signiﬁcantly (p N 0.7) for
women aged 30–39 years. Although screening rates declined over this
period, excisional rates per 10,000 women screened also decreased
signiﬁcantly (p b0.0001) for women aged 15–24 years.
Table 2 gives the number of abnormal index cervical cytology tests
by age and result, and shows the follow-up over a period of 12 months.
Follow-up has been classiﬁed hierarchically as colposcopy with cervical
biopsy and/or ECC, else other gynecologic procedure, else follow-up cy-
tology only, else no-follow-up. Other gynecologic procedures include
endometrial biopsies, vaginal and vulvar biopsies, and hysterectomies.
A small percent (6.6%) of women who underwent excision and had no
cervical biopsy or ECC prior to the excision are included in the
colposcopic biopsy follow-up category, given that they received histo-
logic evaluation of their cytologic abnormalities. Colposcopies without
biopsy or ECC are not reported to the NMHPVPR.
Follow-up with colposcopy and cervical biopsy/ECC increases with
age for all categories of cytologic result except for ASC-US [HPV negative
or unknown] and HSIL (Fig. 1). Follow-up by only repeat cytology after
an abnormal cytology of LSIL or worse wasmore common among youn-
ger women. Notably, 10.3% of women aged 15–20 years with HSIL
cytology were followed only by repeat cytology compared to 4.5% of
women aged 35–39 years. Similarly, lack of follow-up of any kind was
more common among younger women, particularly among those with
LSIL or ASC-H cytology. There was little change between 2007 and
2010 in the percent of womenwith ASC-US+ orworse cytology receiv-
ing follow-up colposcopy with biopsy, except for women 15–20 years
of age (Fig. 2A). In this age group, follow-upwith colposcopy and biopsydecreased signiﬁcantly from46% in 2007 to 26% in 2010 (p b 0.0001). The
proportion of women aged b21 years with preceding abnormal cytology
was as expected and was similar to that observed for other age groups.
For the period of 2007–2011, 43.8% of women aged 15–20 years had a
prior cytology within 3 years of the screening cytology and 8.2% had a
prior abnormal cytology within 3 years. For the more recent period of
2009–2011, 48.6% had a prior cytology within 3 years of the screening
cytology and 10.0% had a prior abnormal cytology within 3 years.
Table 3 displays the likelihood, by age category and overall (ages 15–
39 years), that a woman with a speciﬁc cervical cytology and histology
result will undergo a cervical excisional procedure in the following 12 -
months. As expected, excisional treatment increased with severity of
the preceding cervical histology. The cytology result had no signiﬁcant
effect on the likelihood of excisional treatment for CIN2 and CIN3+his-
tology, but was a signiﬁcant factor for CIN1 and negative histology. Ex-
cisional treatment increased with age in all categories. Table 3 reveals
the importance of the combination of a CIN2 biopsy and a cytology re-
sult less than HSIL (bHSIL) as an indication for excision. The likelihood
of excision following this combination of histology and cytology results
increased from 32.6% at age 15–20 years to 67.8% at age 35–39 years,
and preceded fully one-third (746 of 2236) of all excisional procedures
inwomen aged 15–39 years. Independent of the associated cytology re-
sult, CIN2 was the most common histologic antecedent of excisional
treatment, preceding 41.8% (935 of 2236) of all excisional treatments.
ForwomenwithCIN2biopsy, 7.4%had a prior abnormal cytologywithin
3 years. The rate of excisional treatment for these women was 56.9%
compared to 46.5% for women without prior abnormal cytology. Very
few of these women had persistent CIN. For the period of 2007–2010,
32 of the 1968 women with CIN2 had CIN1 or greater on a prior biopsy
Table 2
One year follow-up of abnormal index cervical screena.
Colposcopy with cervical biopsy/ECC Other gynecologic procedure Follow-up cytology only No follow-up
Age Cytology n % % % % %
15–20 years ASC-US 2329 23.9 5.4 0.1 25.3 69.2
ASC-US+ 2643 27.2 28.8 0.3 22.0 49.0
LSIL 4,160 42.7 35.6 0.4 18.9 45.1
ASC-H 316 3.2 49.7 0.0 16.8 33.5
HSIL 234 2.4 73.5 0.0 10.3 16.2
AGC 49 0.5 55.1 0.0 12.2 32.7
21–24 years ASC-US 2759 27.1 8.3 0.6 29.1 62.1
ASC-US+ 2839 27.9 50.8 0.3 16.3 32.6
LSIL 3641 35.8 54.2 0.4 15.7 29.8
ASC-H 441 4.3 57.8 1.1 12.7 28.3
HSIL 383 3.8 73.4 0.3 8.1 18.3
AGC 104 1.0 53.8 1.0 18.3 26.9
25–29 years ASC-US 3012 33.1 7.0 1.3 27.7 63.9
ASC-US+ 2303 25.3 58.0 0.3 15.7 26.0
LSIL 2707 29.7 58.6 0.7 13.6 27.1
ASC-H 444 4.9 65.8 0.7 10.1 23.4
HSIL 464 5.1 77.8 0.4 6.3 15.5
AGC 171 1.9 56.1 0.6 11.7 31.6
30–34 years ASC-US 2552 41.9 7.0 2.5 25.5 65.0
ASC-US+ 1268 20.8 64.4 1.0 10.9 23.7
LSIL 1444 23.7 62.5 0.6 12.8 24.1
ASC-H 323 5.3 68.4 0.3 12.1 19.2
HSIL 306 5.0 76.1 1.0 6.2 16.7
AGC 196 3.2 60.2 3.6 11.7 24.5
35–39 years ASC-US 2,331 49.4 5.9 3.7 23.6 66.8
ASC-US+ 802 17.0 64.1 2.1 12.3 21.4
LSIL 923 19.6 63.8 1.7 11.9 22.5
ASC-H 226 4.8 73.5 2.2 9.7 14.6
HSIL 224 4.7 79.5 2.2 4.5 13.8
AGC 210 4.5 67.1 5.2 8.6 19.0
Total ASC-US 12,983 32.6 6.8 1.6 26.4 65.2
ASC-US+ 9,855 24.8 49.4 0.5 16.7 33.4
LSIL 12,875 32.3 50.7 0.6 15.7 33.0
ASC-H 1,750 4.4 62.3 0.8 12.3 24.6
HSIL 1,611 4.0 76.0 0.7 7.0 16.3
AGC 730 1.8 60.0 2.7 11.8 25.5
a Follow-up classiﬁcation is hierarchical: colposcopywith cervical biopsy or endocervical curettage (ECC), else other gynecologic procedure, else follow-up cytology, else no follow-up.
Colposcopywithout biopsy or curettage is not ascertained by the NewMexico HPV Pap Registry (NMHPVPR).Womenwith LEEP and no preceding colposcopy are included in the colpos-
copy category. Other gynecologic procedures include endometrial, vaginal, and vulvar biopsies and hysterectomies. Follow-up cytology is deﬁned as cervical cytology within 300 days of
the index cytology. Cytologic results are as follows: atypical squamous cells of unknown signiﬁcance (ASC-US) is negative for high-risk human papillomavirus (HPV) or HPV status un-
known, ASC-US+ is positive for high-risk HPV deﬁned as positive for one or more HPV types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, low-grade intraepithelial lesion
(LSIL), atypical squamous cells-cannot rule out high-grade (ASC-H), atypical glandular cells (AGC), and high-grade intraepithelial lesion (HSIL).
631W. Kinney et al. / Gynecologic Oncology 132 (2014) 628–635within 3 years. When restricting to the more recent period of 2009–
2010, 9 of 861 women with CIN2 had a CIN1 or greater result on a
prior biopsy within 3 years. The median length of follow-up forFig. 1. Percent of women with colposcopic biopsy or endocervical curettage (ECC) within
12 months of abnormal index screening cytology by age of woman and result of cytology.
Cytology results are classiﬁed as ASC-US [atypical squamous cells of undetermined
signiﬁcance, negative for high-risk human papillomavirus (HPV) orHPV status unknown],
ASC-US+ [ASC-US, positive for high-risk HPV], LSIL [low-grade squamous intraepithelial
lesion], ASC-H [atypical squamous cells-cannot rule out high-grade], andHSIL [high-grade
squamous intraepithelial lesion].women with CIN2 was 316 days and 90% were in the range of 62 to
350 days. For comparison, the median number of days between a
CIN2 biopsy and excisional treatment was 43 days.
Histology results of CIN2–3 (n = 317), which are combined with
CIN3+ in Table 3, were followed by excision in 60.3% of cases, which
was similar to that for CIN3+ excluding CIN2–3 (64.0%). The percent
of excisions that were diagnosed as CIN3+ was also similar (55.5% for
CIN2–3 vs. 64.5% for CIN3+ excluding CIN2–3).
The percentage of excisional specimens with CIN3 or greater histol-
ogy (“CIN3+ yield”) is also reported in Table 3. CIN3+ yield increased
not only with the severity of the preceding histology, but also with the
severity of the preceding cytology. With few exceptions CIN3+ yield
from excisionwas signiﬁcantly greater when preceded byHSIL cytology
than by bHSIL cytology.
Time trends in use of excision over the period 2007–2010 are shown
in Table 4 and Fig. 2B, stratiﬁed by age and preceding cytology/histology.
The overall use of excision decreased for women aged 15–24 years but
was limited to those with bHSIL cytology and/or biopsy results bCIN2.
Among women aged 25–39 years, the reduction in use of excision was
seen only for those with bHSIL cytology. Because of the decrease in
screening at all ages and decrease in referral to colposcopy, the absolute
number of excisions decreased in all categories and age groups. Notably
the proportion of LEEPs that were CIN3+ increased from 10.3% to 52.4%
(p b 0∙0001) in women aged 15–20 years but this proportion remained
unchanged in older women (Fig. 2C).
Fig. 2. (A). Percent of women with colposcopic biopsy or endocervical curettage (ECC)
within 12 month of index screening cytology with result of ASC-US+ [atypical squamous
cells of unknown signiﬁcance, high-risk human papillomavirus (HPV) positive] or more
severe by age of woman and year of cytology. (B). Percent of women receiving excisional
treatment (LEEP) following colposcopic biopsy or endocervical curettage (ECC) with
diagnosis of negative, cervical intraepithelial neoplasia grade 1 (CIN1), or cervical
intraepithelial neoplasia grade 2 (CIN2) accompanied by less than high-grade squamous
intraepithelial lesion (bHSIL) cytology. (C). Percent of excisional treatment (LEEP) with
diagnosis of CIN3+ [CIN grade 3 or worse] by age of women and year of biopsy.
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Taken together, these data show some grounds for optimism about
the effect of clinical practice guidelines on the care provided to young
women. The decrease in cervical screening from 2009 to 2011 and the
87% decrease in excisions performed per 10,000 women aged
15–20 years are encouraging, as is the 45% reduction in LEEPs in
women aged 21–24 years. Furthermore, follow-up of abnormal screens
with colposcopy and biopsy in women aged 15–20 years declined by
more than 40% from 2007 to 2010. Also reassuring is the reduction in
the use of excision following biopsies of bCIN2, and biopsies of CIN2
with bHSIL cytology in women aged 15–24 years. Longitudinal follow-up of the New Mexico population through the NMHPVPR provides a
unique opportunity to evaluate real world clinical practice versus cervi-
cal screening guidelines and to measure the impact on population-
based disease outcomes. These data will become increasingly important
to estimating the impact and effectiveness of HPV vaccination given the
concurrent changing landscape of cervical screening in the United
States must be considered.
Despite the documented progress, screening and treatment of
women below the age of 21 years continues to occur. Adherence to cur-
rent US cervical screening guidelines would eliminate screening in
these women, and would eliminate most excisional procedures in the
event that screening was undertaken. While the beneﬁt of cervical
screening at age 21–24 years is difﬁcult to demonstrate, the negative
consequences in terms of the number of excisional procedures
performed are measurable. Moscicki et al. reported that 68% of CIN2 di-
agnosed in the community hospital setting at ages 13–25 years remits
spontaneously in a 36 month period which is consistent with reports
from the ALTS experience [7, 17]. Although it is recognized that the di-
agnosis of individual cases of CIN2 is poorly reproducible [18], from
the population perspective the distinction of CIN2 from CIN3 appears
to confer signiﬁcantly different risk of the presence of CIN3+ on LEEP
histology and, therefore, to have potential clinical beneﬁts, particularly
for the purpose of avoiding overtreatment of younger women.
The observation concerning the importance of CIN2 as an antecedent
to excision is accentuated by the recognition that our analyses did not in-
clude the diagnosis of CIN2-3 within the CIN2 category, despite the fact
that observation in place of treatment is also regarded as an option for
“adolescents and young women” with CIN2-3 [19]. While a minority of
the CIN2 were associated with HSIL cytology, the fact that almost half of
excisions in women 15–39 years (1090 of 2236) were preceded by
bHSIL cytology and biopsies of≤CIN2, suggests that there is an opportu-
nity to signiﬁcantly decrease the harmsof screening but only if the current
distinctions of CIN2 and CIN3 diagnostic categories are fully maintained
versus grouping as “high-grade” histology not otherwise speciﬁed.
In contrast, the potential grouping of CIN2 and bCIN2 biopsies to-
gether as “low-grade” is supported by the observation that low versus
high grade cytology differentiates the risk of ﬁnding CIN3+ on LEEP
histology more effectively than CIN2 versus bCIN2 on biopsy. A biopsy
of bCIN2 and HSIL cytology carries as much risk as CIN2 and HSIL cytol-
ogy. These observations are consistent with the recent recognition of
the imperfect sensitivity of colposcopy [20, 21] and suggestions for im-
provement [22, 23]. Furthermore, the unsurprising demonstration that
the grade of the antecedent cytology effectively predicts risk of CIN3+
in women with CIN2 provides a method of discerning the potential
beneﬁt of excisional treatment without requiring additional testing,
and should be considered in the evolution of clinical guidelines to
promote conservative management of young women with biopsies
less than CIN3 following cytology less severe than HSIL.
The strengths of these observations lie in their completeness, data
quality, longitudinal nature, and scope. Colposcopies without biopsy
and cervical treatment by methods that do not produce a histologic
specimen (cryotherapy and laser ablation, for example) are not report-
ed to the NMHPVPR, which limits assessment of the completeness of
follow-up and treatment of abnormal test results. An additional weak-
ness is the geographical restriction to New Mexico, which may not
reﬂect clinical practice elsewhere in the US. In the absence of any
other data sources about actual fee-for-service clinical practice in the
United States, assertions about generalizability cannot be made or
refuted. The development of programs similar to the NMHPVPR in
other states should be a priority, andwould serve to informprovider ed-
ucation, assessment of the “real world” risks and beneﬁts of screening,
and conceivably inﬂuence reimbursement policy.
The NMHPVPR data presented here does provide guidance about
cervical excision as a consequence of cervical screening at different
ages. If screening is going to continue in the US at ages b25 years,
then these data show that a signiﬁcant number of the excisions in the
Table 3
LEEP within 1 year of abnormal index screen by cytological result and result of follow-up cervical biopsya.
LEEP CIN3+ yield
Age Histology Cytology Screens n % (95% CI) n % (95% CI)
15–20 years CIN3+ HSIL 38 20 52.6 (35.8–69.0) 11 55.0 (31.5–76.9)
bHSIL 88 46 52.3 (41.4–63.0) 17 37.0 (23.2–52.5)
CIN2 HSIL 72 21 29.2 (19.0–41.1) 4 19.0 (5.4–41.9)
bHSIL 261 85 32.6 (26.9–38.6) 16 18.8 (11.2–28.8)
CIN1 HSIL 72 8 11.1 (4.9–20.7) 0 0.0 (0.0–36.9)
bHSIL 1401 25 1.8 (1.2–2.6) 1 4.0 (0.1–20.4)
Negative HSIL 36 2 5.6 (0.7–18.7) 0 0.0 (0.0–84.2)
bHSIL 725 2 0.3 (0.0–1.0) 0 0.0 (0.0–84.2)
No biopsy HSIL 92 4 4.3 (1.2–10.8) 1 25.0 (0.6–80.6)
bHSIL 6946 13 0.2 (0.1–0.3) 2 15.4 (1.9–45.4)
21–24 years CIN3+ HSIL 105 59 56.2 (46.2–65.9) 49 83.1 (71.0–91.6)
bHSIL 178 120 67.4 (60.0–74.2) 64 53.3 (44.0–62.5)
CIN2 HSIL 98 47 48.0 (37.8–58.3) 14 29.8 (17.3–44.9)
bHSIL 503 219 43.5 (39.2–48.0) 39 17.8 (13.0–23.5)
CIN1 HSIL 84 12 14.3 (7.6–23.6) 2 16.7 (2.1–48.4)
bHSIL 1989 34 1.7 (1.2–2.4) 0 0.0 (0.0–10.3)
Negative HSIL 51 10 19.6 (9.8–33.1) 4 40.0 (12.2–73.8)
bHSIL 1188 4 0.3 (0.1–0.9) 0 0.0 (0.0–60.2)
No biopsy HSIL 129 8 6.2 (2.7–11.9) 4 50.0 (15.7–84.3)
bHSIL 5842 18 0.3 (0.2–0.5) 3 16.7 (3.6–41.4)
25–29 years CIN3+ HSIL 155 94 60.6 (52.5–68.4) 77 81.9 (72.6–89.1)
bHSIL 217 141 65.0 (58.2–71.3) 69 48.9 (40.4–57.5)
CIN2 HSIL 123 67 54.5 (45.2–63.5) 20 29.9 (19.3–42.3)
bHSIL 456 234 51.3 (46.6–56.0) 37 15.8 (11.4–21.1)
CIN1 HSIL 87 20 23.0 (14.6–33.2) 5 25.0 (8.7–49.1)
bHSIL 1562 64 4.1 (3.2–5.2) 7 10.9 (4.5–21.2)
Negative HSIL 45 11 24.4 (12.9–39.5) 4 36.4 (10.9–69.2)
bHSIL 1174 6 0.5 (0.2–1.1) 3 50.0 (11.8–88.2)
No biopsy HSIL 141 21 14.9 (9.5–21.9) 12 57.1 (34.0–78.2)
bHSIL 5141 24 0.5 (0.3–0.7) 5 20.8 (7.1–42.2)
30–34 years CIN3+ HSIL 121 77 63.6 (54.4–72.2) 61 79.2 (68.5–87.6)
bHSIL 156 112 71.8 (64.0–78.7) 67 59.8 (50.1–69.0)
CIN2 HSIL 59 33 55.9 (42.4–68.8) 15 45.5 (28.1–63.6)
bHSIL 242 126 52.1 (45.6–58.5) 24 19.0 (12.6–27.0)
CIN1 HSIL 35 8 22.9 (10.4–40.1) 0 0.0 (0.0–36.9)
bHSIL 968 53 5.5 (4.1–7.1) 3 5.7 (1.2–15.7)
Negative HSIL 28 9 32.1 (15.9–52.4) 5 55.6 (21.2–86.3)
bHSIL 819 7 0.9 (0.3–1.8) 1 14.3 (0.4–57.9)
No biopsy HSIL 99 13 13.1 (7.2–21.4) 8 61.5 (31.6–86.1)
bHSIL 3562 17 0.5 (0.3–0.8) 5 29.4 (10.3–56.0)
35–39 years CIN3+ HSIL 89 55 61.8 (50.9–71.9) 42 76.4 (63.0–86.8)
bHSIL 119 73 61.3 (52.0–70.1) 48 65.8 (53.7–76.5)
CIN2 HSIL 43 21 48.8 (33.3–64.5) 6 28.6 (11.3–52.2)
bHSIL 121 82 67.8 (58.7–76.0) 15 18.3 (10.6–28.4)
CIN1 HSIL 22 6 27.3 (10.7–50.2) 3 50.0 (11.8–88.2)
bHSIL 602 48 8.0 (5.9–10.4) 2 4.2 (0.5–14.3)
Negative HSIL 31 14 45.2 (27.3–64.0) 4 28.6 (8.4–58.1)
bHSIL 654 9 1.4 (0.6–2.6) 0 0.0 (0.0–33.6)
No biopsy HSIL 66 14 21.2 (12.1–33.0) 10 71.4 (41.9–91.6)
bHSIL 2969 20 0.7 (0.4–1.0) 6 30.0 (11.9–54.3)
Total CIN3+ HSIL 508 305 60.0 (55.6–64.3) 240 78.7 (73.7–83.1)
bHSIL 758 492 64.9 (61.4–68.3) 265 53.9 (49.3–58.3)
CIN2 HSIL 395 189 47.8 (42.8–52.9) 59 31.2 (24.7–38.3)
bHSIL 1583 746 47.1 (44.6–49.6) 131 17.6 (14.9–20.5)
CIN1 HSIL 300 54 18.0 (13.8–22.8) 10 18.5 (9.3–31.4)
bHSIL 6522 224 3.4 (3.0–3.9) 13 5.8 (3.1–9.7)
Negative HSIL 191 46 24.1 (18.2–30.8) 17 37.0 (23.2–52.5)
bHSIL 4560 28 0.6 (0.4–0.9) 4 14.3 (4.0–32.7)
No biopsy HSIL 527 60 11.4 (8.8–14.4) 35 58.3 (44.9–70.9)
bHSIL 24,460 92 0.4 (0.3–0.5) 21 22.8 (14.7–32.8)
Although LEEPS performedwithin 1 year of the index cytology accounted for themajority (70%), somewomen received LEEP treatment more than 1 year after the index cytology. In the
second year following the index cytology, the percent of women receiving LEEP increased from 35.2% at 12 months to 39% at 24 months for HSIL cytology, from 17.9% to 21.1% for ASC-H,
from 5.3% to 6.7% for ASC-US+ [high-risk HPV positive] and LSIL combined, from 9.6% to 11.2% for AGC, and from 0.5% to 1.1% for ASC-US [high-risk HPV negative or unknown].
a Histology result is the most severe diagnosis from any cervical biopsy or ECC done after the index cytology and before the LEEP. Cytology result is the most severe diagnosis from the
index cytology and any follow-up cytology done before LEEP. Cervical intraepithelial neoplasia grade 3 (CIN3+) includes CIN3, CIN grades 2–3 (CIN2–3), carcinoma in situ (CIS), adeno-
carcinoma in situ (AIS), and cancer; cervical intraepithelial neoplasia grade 2 (CIN2) includes CIN2 and CIN grades 1–2 (CIN1–2); abbreviations for cytologic results are as outlined in
Table 2, less than high-grade squamous intraepithelial lesions (bHSIL) cytology includes ASC-US, ASC-US+, LSIL, ASC-H, and AGC.
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current clinical practice guidelines. Importantly these data also suggest
that the proposal for changes regarding categories for cervical histology
that equate CIN3with all or part of CIN2 [24] obviates the ability toman-
age CIN3 differently than CIN2 or CIN2/3. The newly recommended useof p16 to in effect predict risk and clinical course does not resolve this
issue, as there is no data on natural history and disease outcomes strat-
iﬁed by p16 status, and much of the p16 positive CIN2 must also be re-
gressive based on the high rates of regression observed in CIN2
unqualiﬁed by p16 testing [7, 18]. If these recommendations are
Table 4
Time trends in percent of abnormal index cytology followed by a LEEP within 1 yeara.
15–24 years 25–39 years
Histology Cytology Year Screens LEEPs % LEEPs (95% CI) Screens LEEPs % LEEPs (95% CI)
CIN3+ HSIL 2007 37 20 54.1 (36.9–70.5) 98 72 73.5 (63.6–81.9)
2008 48 30 62.5 (47.4–76.0) 98 59 60.2 (49.8–70.0)
2009 31 15 48.4 (30.2–66.9) 92 49 53.3 (42.6–63.7)
2010 27 14 51.9 (31.9–71.3) 77 46 59.7 (47.9–70.8)
bHSIL 2007 76 46 60.5 (48.6–71.6) 101 70 69.3 (59.3–78.1)
2008 70 50 71.4 (59.4–81.6) 129 81 62.8 (53.8–71.1)
2009 70 38 54.3 (41.9–66.3) 128 91 71.1 (62.4–78.8)
2010 50 32 64.0 (49.2–77.1) 134 84 62.7 (53.9–70.9)
CIN2 HSIL 2007 63 21 33.3 (22.0–46.3) 59 32 54.2 (40.8–67.3)
2008 50 25 50.0 (35.5–64.5) 65 43 66.2 (53.4–77.4)
2009 28 10 35.7 (18.6–55.9) 63 30 47.6 (34.9–60.6)
2010 29 12 41.4 (23.5–61.1) 38 16 42.1 (26.3–59.2)
bHSIL 2007 237 100 42.2 (35.8–48.8) 213 117 54.9 (48.0–61.7)
2008 229 101 44.1 (37.6–50.8) 201 121 60.2 (53.1–67.0)
2009 166 67 40.4 (32.8–48.2) 202 110 54.5 (47.3–61.5)
2010 132 36 27.3 (19.9–35.7) 203 94 46.3 (39.3–53.4)
CIN1, negative, no biopsy HSIL 2007 167 21 12.6 (8.0–18.6) 172 33 19.2 (13.6–25.9)
2008 123 11 8.9 (4.5–15.4) 141 33 23.4 (16.7–31.3)
2009 103 9 8.7 (4.1–15.9) 134 28 20.9 (14.4–28.8)
2010 71 3 4.2 (0.9–11.9) 107 22 20.6 (13.4–29.5)
bHSIL 2007 5122 32 0.6 (0.4–0.9) 4686 97 2.1 (1.7–2.5)
2008 4843 35 0.7 (0.5–1.0) 4411 72 1.6 (1.3–2.1)
2009 4613 16 0.3 (0.2–0.6) 4376 43 1.0 (0.7–1.3)
2010 3513 13 0.4 (0.2–0.6) 3978 36 0.9 (0.6–1.3)
a Histology result is the most severe diagnosis from any cervical biopsy or ECC done after the index cytology and before the LEEP. Cytology result is the most severe diagnosis from the
index cytology and any follow-up cytology done before LEEP. Abbreviations are as detailed for Table 3, CIN3+ includes CIN3, CIN2–3, CIS, AIS, and cancer; CIN2 includes CIN2 and CIN1–2;
bHSIL cytology includes ASC-US, ASC-US+, LSIL, ASC-H, and AGC.
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speciﬁcation of CIN grade being optional), then reduction of the potential
harms associated with screening women in their childbearing years can
only be realized by decreasing screening itself, rather than encouraging
more appropriate responses to the lesser histologic abnormalities that
precede the majority of LEEPs in the youngest women.
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